CureVac (NASDAQ:CVAC) Shares Gap Down to $3.09

CureVac (NASDAQ:CVAC) shares gapped down before the market opened on Friday . The stock had previously closed at $3.09, but opened at $3.02. CureVac shares last traded at $3.13, with a volume of 109,813 shares changing hands.

Wall Street Analyst Weigh In

Separately, JMP Securities lowered their price objective on shares of CureVac from $18.00 to $16.00 and set a “market outperform” rating on the stock in a research report on Friday, August 16th.

CureVac Trading Up 6.5 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.28. The firm has a fifty day simple moving average of $3.32 and a two-hundred day simple moving average of $3.29. The firm has a market capitalization of $736.57 million, a P/E ratio of -2.47, a price-to-earnings-growth ratio of 2.15 and a beta of 2.62.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). CureVac had a negative return on equity of 57.18% and a negative net margin of 422.66%. The firm had revenue of $15.55 million for the quarter, compared to the consensus estimate of $10.07 million. On average, equities research analysts anticipate that CureVac will post 0.05 earnings per share for the current fiscal year.

Institutional Trading of CureVac

Hedge funds and other institutional investors have recently modified their holdings of the business. Ballentine Partners LLC bought a new position in CureVac in the 1st quarter worth approximately $38,000. Bank of New York Mellon Corp purchased a new stake in shares of CureVac during the second quarter worth $54,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of CureVac in the fourth quarter worth $68,000. Signaturefd LLC grew its position in shares of CureVac by 232.0% in the second quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock valued at $75,000 after purchasing an additional 15,403 shares in the last quarter. Finally, Aristides Capital LLC purchased a new position in shares of CureVac in the fourth quarter valued at $100,000. Institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.